The Potential Effects of IGF-1 and GH on Patients With Chronic Heart Failure

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Cardiovascular Pharmacology and Therapeutics

• Publication date

  2012-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1074248411402078PMID 21454724
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immune Modulation in Heart Failure: Past Challenges and Future Hopes

  2011cited by this paper
• Heart disease and stroke statistics--2011 update: a report from the American Heart Association.

  2011cited by this paper
• Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting.

  2010cited by this paper
• p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment.

  2010cited by this paper
• Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting

  2010cited by this paper
• Insulin‐like growth factor axis (insulin‐like growth factor‐I/insulin‐like growth factor‐binding protein‐3) as a prognostic predictor of heart failure: association with adiponectin

  2010cited by this paper
• Association of metabolic syndrome with insulin-like growth factors among adults in the US

  2009cited by this paper
• IGF-I replacement therapy in children with congenital IGF-I deficiency (Laron syndrome) maintains heart dimension and function.

  2009cited by this paper
• Treatment of dwarfism with recombinant human insulin-like growth factor-1.

  2009cited by this paper
• Arterial pulse wave velocity, inflammatory markers, pathological GH and IGF states, cardiovascular and cerebrovascular disease

  2008cited by this paper
• Growth hormone therapy in congestive heart failure due to left ventricular systolic dysfunction: a meta-analysis.

  2008cited by this paper
• Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.

  2007cited by this paper
• Cardiac-specific overexpression of insulin-like growth factor 1 attenuates aging-associated cardiac diastolic contractile dysfunction and protein damage.

  2007cited by this paper
• Waste management - cytokines, growth factors and cachexia.

  2006cited by this paper
• Growth hormone-induced reduction of soluble apoptosis mediators is associated with reverse cardiac remodelling and improvement of exercise capacity in patients with idiopathic dilated cardiomyopathy

  2005cited by this paper
• Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and cardiovascular disease risk factors in young black men and white men: the CARDIA Male Hormone Study.

  2004cited by this paper
• IGF-I prevents glutamate-induced motor neuron programmed cell death.

  2004cited by this paper
• Insulin-Like Growth Factor-1 as a Vascular Protective Factor

  2004cited by this paper
• Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)

  2004cited by this paper
• Combined growth hormone/insulin-like growth factor I in addition to glutamine-supplemented TPN results in net protein anabolism in critical illness.

  2004cited by this paper
• Hormonal profile in patients with congestive heart failure.

  2003cited by this paper
• Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial

  2003cited by this paper
• Administration of growth hormone to patients with advanced cardiac heart failure: effects upon left ventricular function, exercise capacity, and neurohormonal status.

  2003cited by this paper
• Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study.

  2003cited by this paper
• Inflammation, hormones, and body composition at a crossroad.

  2003cited by this paper
• Growth hormone resistance in chronic heart failure and its therapeutic implications.

  2003influential reference
• Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure.

  2002cited by this paper
• Low Serum Insulin-Like Growth Factor I Is Associated With Increased Risk of Ischemic Heart Disease: A Population-Based Case-Control Study

  2002cited by this paper
• Heart Disease : A Population-Based Case-Control Study Low Serum Insulin-Like Growth Factor I Is Associated With Increased Risk of Ischemic

  2002cited by this paper
• Insulin-like growth factor 1 (IGF-1): a growth hormone

  2001cited by this paper
• Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone.

  2001cited by this paper
• Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction.

  2001cited by this paper
• Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity.

  2001cited by this paper
• Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial.

  2000cited by this paper
• A placebo-controlled study of growth hormone in patients with congestive heart failure.

  1998cited by this paper
• Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles.

  1998cited by this paper
• Serum free and total insulin-like growth factor-I, insulin-like growth factor binding protein-1 and insulin-like growth factor binding protein-3 Levels in healthy elderly individuals. Relation to self-reported quality of health and disability.

  1998cited by this paper
• Serum Free and Total Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-1 and Insulin-Like Growth Factor Binding Protein-3Levels in Healthy Elderly Individuals

  1998cited by this paper
• Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy.

  1998cited by this paper
• Haemodynamic effects of intravenous growth hormone in congestive heart failure.

  1997cited by this paper
• Wasting as independent risk factor for mortality in chronic heart failure.

  1997influential reference
• Insulin-like growth factor-1 and angiographically documented coronary artery disease

  1996cited by this paper
• A preliminary study of growth hormone in the treatment of dilated cardiomyopathy.

  1996cited by this paper
• Insulin-like growth factor-I and angiographically documented coronary artery disease.

  1996cited by this paper
• Insulinlike Growth Factor‐I Induces Hypertrophy With Enhanced Expression of Muscle Specific Genes in Cultured Rat Cardiomyocytes

  1993cited by this paper

• Association of insulin and GH/IGF-1 derangements and heart failure: a narrative review

  2026cites this paper
• IGF-1 promotes cell surface expression of HCN4 pacemaker channels contributing to tachycardia.

  2025cites this paper
• Impact of different hormones on the regulation of nitric oxide in diabetes.

  2024cites this paper
• Insulin-like Growth Factor-1 and Myocardial Remodeling in Patients with Chronic Heart Failure of Ischemic Origin

  2022cites this paper
• Estimating the impact of drug addiction causes heart damage

  2022cites this paper
• Association between insulin-like growth factor-1 and cardiovascular events: a systematic review and dose–response meta-analysis of cohort studies

  2022cites this paper
• Insulin-like growth factor-1 directly affects cardiac cellular remodelling via distinct pathways

  2021cites this paper
• The effects of melatonin on neurohormonal regulation in cardiac cachexia: A mechanistic review

  2019influential citation
• Effects of IGF-1 on the cardiovascular system.

  2019cites this paper
• IMMUNOLOGICAL STUDY OF CORONARY ARTERY DISEASE ASSOCIATED WITH DIABETES MELLITUS TYPE II IN IRAQI PATIENTS

  2018cites this paper
• Relationship of IGF-1 and CKMB in Ischemic heart disease subjects

  2018cites this paper
• Insulin‐like growth factor 1 prevents diastolic and systolic dysfunction associated with cardiomyopathy and preserves adrenergic sensitivity

  2016cites this paper
• The insulin-like growth factor I system: physiological and pathophysiological implication in cardiovascular diseases associated with metabolic syndrome.

  2015cites this paper
• Paracrine Engineering of Human Cardiac Stem Cells with Insulin-Like Growth Factor 1 Promotes Cell Survival to Enhance Myocardial Repair

  2014cites this paper
• Biomarkers for cardiac cachexia: reality or utopia.

  2014cites this paper
• New insights into IGF-1 signaling in the heart.

  2014cites this paper
• Growth Properties of Cardiac Stem Cells Are a Novel Biomarker of Patients’ Outcome After Coronary Bypass Surgery

  2014cites this paper
• Molecular targets of current and prospective heart failure therapies

  2013cites this paper
• New Approaches to Treating Cardiac Cachexia in the Older Patient

  2013cites this paper
• Repairing a "broken heart" with hormone replacement therapy: case report of cardiogenic shock due to undiagnosed pituitary insufficiency.

  2012cites this paper
• Circadian Rhythm of Acylated Ghrelin, Leptin, Growth Hormone, IGF-1, IGFBP-1, and IGFBP-3 in Chronic Heart Failure Patients and Healthy Subjects

  2011cites this paper
• Circadian rhythm of acylated ghrelin, leptin, growth hormone, IGF-1, IGFBP-1 and IGFBP-3.

  2011cites this paper